Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis

  • 1Email author,
  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 3,
  • 4 and
  • 5
BMC Pulmonary Medicine201515:145

https://doi.org/10.1186/s12890-015-0138-4

  • Received: 20 February 2015
  • Accepted: 2 November 2015
  • Published:
Open Peer Review reports

Abstract

Background

Increasing evidence suggests pharmacological treatments may impact on overall survival in Chronic Obstructive Pulmonary Disease (COPD) patients. Individual clinical trials are rarely powered to detect mortality differences between treatments and may not include all treatment options relevant to healthcare decision makers.

Methods

A systematic review was conducted to identify RCTs of COPD treatments reporting mortality; evidence was synthesised using network meta-analysis (NMA). The analysis included 40 RCTs; a quantitative indirect comparison between 14 treatments using data from 55,220 patients was conducted.

Results

The analysis reported two treatments reducing all-cause mortality; salmeterol/fluticasone propionate combination (SFC) was associated with a reduction in mortality versus placebo in the fixed effects (HR 0.79; 95 % Crl 0.67, 0.94) but not the random effects model (0.79; 0.56, 1.09). Indacaterol was associated with a reduction in mortality versus placebo in fixed (0.28; 0.08 to 0.85) and random effects (0.29; 0.08, 0.89) models. Mean estimates and credible intervals for hazard ratios for indacaterol versus placebo are based on a small number of events; estimates may change when the results of future studies are included. These results were maintained across a variety of assumptions and provide evidence that SFC and indacaterol may lead to improved survival in COPD patients.

Conclusion

Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality. Further research is warranted to strengthen this conclusion.

Keywords

  • COPD
  • COPD treatment
  • Systematic review
  • Meta-analysis
  • Mortality

Background

Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity across the world, and the third leading cause of death globally [1, 2]. Primary prevention by a combination of reducing tobacco exposure, decreasing contact with biomass fuels and noxious gases together with improved child health are the most effective ways of decreasing this burden in the longer term, although it takes time for the benefits of interventions on mortality to become apparent [3, 4]. In patients with symptomatic COPD the impact of specific medications on decreasing the risk of dying is an important consideration and merits scientific consideration. The evidence on mortality reduction from individual clinical trials in COPD is inconclusive with relatively few studies of duration and sample size sufficient to demonstrate an impact [5].

Network meta-analysis (NMA) provides a statistical approach to combining direct and indirect trial evidence to generate relative treatment effects between different drugs on outcomes of interest. In the absence of head-to-head trials including all comparators, NMA has been recommended by reimbursement agencies in the UK and Germany [6, 7] and endorsed by influential bodies such as ISPOR [8]. NMA has been applied to COPD mortality data on two previous occasions [9, 10].

We conducted a systematic review and network meta-analysis (NMA) designed to assess whether pharmacotherapy affects mortality reported in COPD clinical trials. NMA was then used to allow all treatment options to be compared in a single analysis [1113]. The analysis combines survival data reported in two different forms: total number of deaths (r) from (n) subjects subsequently referred to as the ‘binary endpoint’, and hazard ratios which describe the impact of treatment on time to death and account for censoring. Although hazard ratios are more informative they are not reported in all studies and the inclusion of binary data enables the maximum number of trials to be included. Sensitivity analyses permitted us to analyse the robustness of the results to various assumptions supporting the base case analysis.

Primarily, our objective was to estimate the impact of specific COPD treatments on patient mortality using NMA. Secondly, we explored the strengths and limitations of undertaking and interpreting NMA in this context.

Methods

Systematic review

A systematic review was conducted to identify randomised, blinded trials of COPD patients treated with tiotropium, beclomethasone, budesonide, fluticasone propionate, triamcinolone, bambuterol, formoterol, salmeterol, salbutamol, indacaterol, theophylline, roflumilast, indacaterol maleate, ipratropium bromide, vilanterol trifenatate, fluticasone furoate or placebo. Dosing and administration method were not specified in the inclusion criteria. Combinations of the listed interventions were allowed; dose comparison studies were not included unless another listed intervention was also incorporated in the study. Studies were required to report all-cause mortality in binary or hazard ratio form for at least 24 weeks of follow-up; mortality could be reported as a study outcome or as a serious adverse event. Only English language full publications were included.

EMBASE (1988), MEDLINE, MEDLINE In-Progress (1946) and CENTRAL (1898) were searched from database inception to October 2012. Searches combined controlled-vocabulary and free-text terms for COPD and the treatments of interest; RCT filters were used in EMBASE and MEDLINE. Full publications were reviewed for inclusion by two analysts (JT and JC). Data was extracted from eligible trials by one analyst with validation conducted by the second analyst. Dosages of the same therapy were combined for the purposes of the analysis (indacaterol (150 μg od, 300 μg od, 600 μg od), budesonide (200 μg bid, 400 μg bid, 1200 μg od for 6 months followed by 800 μg od for 30 months), fluticasone propionate (250 μg bid, 500 μg bid), salmeterol (50 μg bid, 100 μg bid), formoterol (6 μg bid, 12 μg bid, 24 μg bid) and salmeterol fluticasone propionate combination (SFC) (50/ 250 μg bid, 50/ 500 μg bid)). The Cochrane risk of bias tool was used to assess methods of randomisation, allocation concealment, blinding, patient follow-up and incomplete reporting [14].

Statistical analysis

Binary mortality data: total number of deaths (r) from (n) subjects, and hazard ratios with reported confidence intervals from published studies meeting our inclusion criteria were used as inputs to the analysis. We preferred hazard ratios over binary data where reported. Hazard ratios were taken from the Cox proportional-hazards models as these were consistently reported, in particular the Cox model for TORCH was preferred over that calculated directly from the Kaplan Meier in accordance with the other studies which reported HRs. Hazard ratio data and binary data were combined using the methodology established in Woods [15] which also appropriately incorporates multi-arm trials. Estimated treatment effects were synthesised using network meta-analysis (NMA) in a Bayesian multilevel framework. This method allows simultaneous comparison of outcomes of multiple treatments from trials comparing different sets of treatment options (providing a connected network of treatments can be formed) whilst retaining within-trial randomisation. A study protocol was written and reviewed prior to initiating the systematic review and analysis. Full details of the statistical method and the model code are provided in the Additional file 1.

The base case analysis included all RCTs meeting our inclusion criteria using the intention to treat (ITT) results from these studies, combining different licensed doses of the same medicines as single comparators. Results are presented for active treatments relative to placebo (reference).

Sensitivity analyses

The following pre-planned analyses were conducted to examine the sensitivity of the study results to various assumptions:
  1. (A)

    Including on-treatment (OT) mortality (excluding deaths that occurred to patients who ceased to receive the allocated study treatment) results in preference to ITT results where available.

     
  2. (B)

    Meta-regression controlling for differences in COPD severity assuming a common covariable effect across treatments (assessed by baseline FEV1 % predicted – mean value per study)

     
  3. (C)

    Excluding studies where patients had high lung function at baseline (mean FEV1 % predicted >65 %)

     
  4. (D)

    Excluding studies where patients received unlicensed doses

     
  5. (E)

    Excluding studies of less than 48 weeks duration

     
  6. (F)

    Excluding studies not powered to detect a difference in mortality

     
  7. (G)

    Excluding studies that failed to meet our specified quality assessment criteria (i.e. 2 or more components of the assessment had a high or unclear risk of bias) as assessed by the Cochrane Collaboration risk of bias [14]

     
  8. (H)

    Including studies from the Dong [10] NMA for which mortality data were unavailable in the primary publication. Dong [10] cited a variety of sources for these data, including contacting the study authors and searching website and clinical trial registers; these were not included in the present base case analysis

     
  9. (I)

    Separating patients treated with tiotropium by type of inhaler used (SoftMist or HandiHaler). Safety concerns (increased mortality risk) had at the time of the present analysis been raised around the SoftMist inhaler [16]. We also incorporated the results of TIOSPIR [17], a RCT of over 17,000 subjects designed to evaluate efficacy and safety of the two different inhalers, in this sensitivity analysis. TIOSPIR was not published until the final writing up of the present study.

     

Statistical models were fitted using WinBUGS [18]. As the present study is a Bayesian analysis we refer to credible intervals (the probability that the true value is contained within the interval) rather than confidence intervals; instead of statistically significant differences, we refer to important differences (95 % credible interval for hazard ratio does not cross 1.0).

Both fixed and random effect models were fitted. Fixed effect assumes there is one true effect of each treatment and that variation around this is attributed to chance whilst random effects assume a distribution of effects and that variance between studies is attributed to heterogeneity. Larger studies are thus attached relatively less weight in random effects model [19]. The Deviance Information Criteria (DIC) was calculated for each model and used to assess whether any model should be preferred [20]. Each model was run for a burn-in period of 40,000 simulations, which were then discarded, with parameter nodes monitored for a further 200,000 simulations. Caterpillar and Brooks - Gelman - Rubin (BGR) plots were used to compare results obtained using different initial values, thus ensuring that the models had converged [21].

Results and discussion

Systematic review

The systematic review identified 42 studies reporting all-cause mortality in COPD patients (Fig. 1; reasons for excluding full publications: Additional file 2: Table S1). Demographic characteristics of subjects (age, gender) are reported in Table 1; the impact of differences in baseline FEV1 % predicted is assessed in sensitivity analyses B and C. The proportion of current smokers was similar across trials, but three trials (all with patients with less impairment of lung function) reported levels in excess of 75 % [2224].
Fig. 1
Fig. 1

PRISMA diagram showing inclusion of studies at each stage of the systematic review and network meta-analysis

Table 1

Baseline characteristics of included studies and all-cause mortality (binary data)

     

Baseline characteristics

All-cause mortality (binary)

References

Trial

Treatment

Dose

Study duration (weeks)

n

Mean age (yr.)

Women (%)

Current smokers (%)

FEV1 (mean % predicted)

Subjects

Deaths - ITT

Deaths – OT

[53]

Aaron 2007

Tiotropium + Salmeterol

18 μg od/50 μg bid

52

148

67.6

42.6

24.3

41.2

148

6

NR

Tiotropium + SFC

18 μg od/50/500 μg bid

 

145

67.5

42.1

32.4

42.2

145

6

NR

Tiotropium + Placebo

18 μg od

 

156

68.1

46.2

26.9

42.1

156

4

NR

[40]

Anzueto 2009

SFC

50/250 μg bid

52

394

65.4

49.0

42.0

41.2

394

4

NR

Salmeterol

50 μg bid

 

403

65.3

43.0

43.0

40.0

403

6

NR

[54]

Bateman 2010

Tiotropium

5 μg od

48

1952

64.8

21.9

35.7

45.2

1952

52

NR

Placebo

-

 

1965

64.8

23.0

35.9

45.4

1965

38

NR

[55]

ISOLDE (Burge 2000)

Fluticasone Propionate

500 μg bid

156

376

63.7

25.0

36.4

50.3

372

32

NR

Placebo

-

 

375

63.8

26.0

39.2

50.0

370

36

NR

[56]

Calverley 2003

Budesonide + Formoterol

320/9 μg bid

52

254

64.0

22.0

33.0

36.0

254

5

NR

Budesonide

400 μg bid

 

257

64.0

26.0

39.0

36.0

257

6

NR

Formoterol

9 μg bid

 

255

63.0

25.0

36.0

36.0

255

13

NR

Placebo

-

 

256

65.0

25.0

30.0

36.0

256

5

NR

[5]

TORCH* (Calverley 2007)

Fluticasone Propionate

500 μg bid

156

1534

65.0

25.0

43.0

44.1

1534

246

NR

Salmeterol

50 μg bid

 

1521

65.1

24.0

43.0

43.6

1521

205

NR

SFC

50/500 μg bid

 

1533

65.0

25.0

43.0

44.3

1533

193

NR

Placebo

-

 

1524

65.0

24.0

43.0

44.1

1524

231

NR

[57]

Calverley 2007

Roflumilast

500 μg od

52

760

65.0

25.0

38.0

41.0

760

12

NR

Placebo

  

753

64.0

24.0

35.0

41.0

753

20

NR

[58]

M2-124 (Calverley 2009)

Roflumilast

500 μg od

52

765

64.0

29.0

48.0

37.6

765

17

NR

Placebo

  

758

63.0

29.0

48.0

37.5

758

17

NR

M2-125 (Calverley 2009)

Roflumilast

500 μg od

52

772

64.0

21.0

35.0

34.6

772

25

NR

 

Placebo

  

796

64.0

19.0

35.0

35.3

796

25

NR

[59]

Calverley 2010

Beclomethasone + Formoterol

200/12μg bid

48

232

63.0

20.7

38.8

41.9a

232

2

NR

Budesonide + Formoterol

400/12μg bid

 

238

64.1

18.5

36.1

42.3a

238

4

NR

Formoterol

12 μg bid

 

233

63.7

18.9

37.3

42.5a

233

0

NR

[49]

Campbell 2005

Formoterol bid + Formoterol

9 μg bid / 4.5 μg as needed

26

225

60.0

29.0

56.0

54.4b

225

1

NR

Formoterol bid + Terbutaline

9μg bid / 0.5 mg as needed

 

215

60.0

39.0

54.0

53.0b

215

2

NR

Placebo + Terbutaline

0.5 mg as needed

 

217

60.0

27.0

55.0

54.1b

217

0

NR

[26]

Casaburi 2005

Tiotropium

18 μg od

25

55

65.9

45.5

29.1

32.6b

55

1

NR

Placebo

-

 

53

67.3

41.5

18.9

36.2b

53

0

NR

[27]

Chan 2007

Tiotropium

18 μg od

48

608

66.8

41.0

32.0

39.4b

608

15

13

 

Placebo

-

 

305

66.9

39.0

30.0

39.3b

305

4

2

[60]

Choudhury 2007

Fluticasone Propionate

500 μg bid

52

128

67.6

52.0

40.6

53.2

128

3

NR

Placebo

-

 

132

67.3

44.0

35.6

55.0

132

0

NR

[28]

INVOLVE (Dahl 2010)

Indacaterol (300)

300μg od

52

437

64.0

19.7

NR

51.5

437

1

1

Indacaterol (600)

600μg od

 

425

63.0

23.1

NR

50.8

428

1

0

Formoterol

12μg (bid)

 

434

64.0

19.8

NR

52.5

435

5

3

Placebo

-

 

432

63.0

18.5

NR

52.0

432

5

4

[29]

Donohue 2002

Salmeterol

50 μg bid

26

213

64.6

25.0

NR

40.2bc

213

3

NR

Tiotropium

18 μg od

 

209

64.5

26.0

NR

40.2bc

209

0

NR

Placebo

-

 

201

65.6

25.0

NR

40.2bc

201

4

NR

[30]

INHANCE (Donohue 2010)

Indacaterol (150)

150 μg od

26

416

63.4

37.7

NR

56.1

416

1

NR

Indacaterol (300)

300 μg od

 

416

63.3

36.8

NR

56.3

416

0

NR

Tiotropium

18 μg od

 

415

64.0

35.2

NR

53.9

415

2

NR

Placebo

-

 

418

63.6

39.0

NR

56.1

418

0

NR

[31]

Ferguson 2008

SFC

250/50 μg bid

52

394

64.9

42.0

40.0

39.8

394

6

NR

Salmeterol

50 μg bid

 

388

65.0

48.0

38.0

40.6

388

3

NR

[32]

Hanania 2003

Fluticasone Propionate

250 μg bid

24

183

63.0

34.0

48.0

42.0b

183

0

NR

Salmeterol

50 μg bid

 

177

64.0

42.0

51.0

42.0

177

0

NR

SFC

250 / 50 μg bid

 

178

63.0

39.0

43.0

41.0

178

0

NR

Placebo

-

 

185

65.0

32.0

47.0

42.0b

185

0

NR

[33]

VIVACE (Kardos 2007)

Salmeterol

50 μg bid

44

487

64.0

22.4

44.4

40.3

487

9

NR

SFC

50/500 μg bid

 

507

63.8

26.0

40.6

40.4

507

7

NR

[41]

Kerstjens 1992

Ipratropium Bromide + Terbutaline

800/2000 μg bid

130

92

38.9

36.0

34.0

63.3a

92

0

NR

Beclomethasone + Terbutaline

160/2000 μg bid

 

91

40.2

35.0

36.0

64.6a

91

0

NR

Placebo + Terbutaline

na/2000 μg bid

 

91

39.6

36.0

37.0

63.3a

91

0

NR

[42]

INLIGHT-2 (Kornmann 2011)

Indacaterol

150 μg od

26

330

63.0

28.0

46.0

54.0

330

1

NR

Salmeterol

50 μg bid

 

333

63.0

25.0

46.0

53.0

333

0

NR

Placebo

-

 

335

64.0

23.0

45.0

53.0

335

3

NR

[34]

Mahler 2002

Fluticasone Propionate

500 μg bid

24

168

64.4

39.0

46.0

41.0b

168

0

NR

Salmeterol

50 μg bid

 

160

63.5

36.0

46.0

40.0b

160

0

NR

SFC

50 / 500 μg bid

 

165

61.9

38.0

46.0

41.0b

165

0

NR

Placebo

-

 

181

64.0

25.0

54.0

41.0b

181

3

NR

[61]

Niewoehner 2005

Tiotropium

-

26

914

67.6

2.0

29.0

35.6b

914

22

NR

Placebo

18 μg od

 

915

68.1

1.0

30.0

35.6b

915

19

NR

[22]

EUROSCOP (Pauwels 1999)

Budesonide

400μg bid

156

634

52.5

26.5

100.0

76.8a

634

8

NR

Placebo

-

 

643

52.4

27.8

100.0

76.9a

643

10

NR

[35]

Rennard 2009

Budesonide + Formoterol

320/9 μg bid

52

494

63.2

37.7

39.1

38.6

494

8

3

Budesonide + Formoterol

160/9 μg bid

 

494

63.6

37.2

41.9

39.6

494

8

6

Formoterol

9 μg bid

 

495

62.9

34.7

45.1

39.3

495

6

2

Placebo

-

 

481

62.9

34.7

43.9

40.8

481

8

4

[36]

FICOPD II (Rossi 2002)

Formoterol 12

12 μg bid

52

211

63.0

13.0

NR

47.0b

211

3

NR

Formoterol 24

24 μg bid

 

214

62.0

17.0

NR

47.0b

214

1

NR

Theophylline

200/300 mg bid

 

209

64.0

18.0

NR

46.0b

209

0

NR

Placebo

-

 

220

63.0

21.0

NR

49.0b

220

0

NR

[62]

Schermer 2009

Fluticasone Propionate

500 μg bid

156

94

58.4

27.0

62.0

68.7b

94

8

NR

Placebo

-

 

96

59.6

32.0

51.0

71.4b

96

3

NR

[23]

Shaker 2009

Budesonide

400 μg bid

208

127

63.6

38.0

100.0

51.0b

127

5

NR

Placebo

-

 

127

63.6

46.0

100.0

53.0b

127

5

NR

[43]

Stockley 2006

Salmeterol

50 μg bid

52

318

62.3

24.0

46.0

45.8b

216

6

NR

Placebo

-

 

316

62.4

23.0

47.0

46.1b

222

5

NR

[37]

Szafranski 2003

Budesonide + Formoterol

320/9 μg bid

52

208

64.0

24.0

30.0

36.0b

208

6

NR

Budesonide

400 μg bid

 

198

64.0

20.0

36.0

37.0b

198

5

NR

Formoterol

9 μg bid

 

201

63.0

24.0

38.0

36.0b

201

6

NR

Placebo

-

 

205

65.0

17.0

34.0

36.0b

205

9

NR

[63]

Tashkin 2008

Budesonide + Formoterol

320/9 μg bid

26

277

63.1

32.1

44.4

39.1

277

3

NR

Budesonide + Formoterol

160/9 μg bid

 

281

63.6

35.6

44.8

39.9

281

4

NR

Budesonide + Formoterol

320 + 9 μg bid (separate)

 

287

63.7

25.8

41.5

39.2

287

0

NR

Budesonide

320 μg bid

 

275

63.4

32.4

42.9

39.7

275

2

NR

Formoterol

9 μg bid

 

284

63.5

34.5

41.9

39.6

284

1

NR

Placebo

-

 

300

63.2

31.0

39.7

41.3

300

1

NR

[64, 65]

UPLIFT (Tashkin 2008/Celli 2009)

Tiotropium

18 μg od

208

2986

64.5

24.6

29.3

47.7

2987

446

381

Placebo

-

 

3006

64.5

26.1

29.9

47.4

3006

495

411

[44]

Tonnel 2008

Tiotropium

18 μg od

39

266

64.9

13.2

23.7

47.5b

266

3

NR

Placebo

  

288

63.5

14.6

30.2

46.2b

288

6

NR

[45]

COPE (van der Valk 2002)

Fluticasone Propionate

500 μg bid

26

123

64.1

14.6

22.0

57.5

123

1

NR

Placebo

-

 

121

64.0

16.5

33.3

56.1

121

1

NR

[46]

CCLS (Vestbo 1999)

Budesonide

800 μg od + 400 μg od for 6 months; 400 μg bid for 30 month

156

145

59.0

41.4

75.9

86.2

145

4

NR

Placebo

-

 

145

59.1

37.9

77.2

86.9

145

5

NR

[38]

Vogelmeier 2008

Formoterol

10 μg bid

24

210

61.8

24.3

NR

51.6b

210

0

NR

Tiotropium

18 μg od

 

221

63.4

20.8

NR

51.6b

221

0

NR

Tiotropium + Formoterol

18 μg od/10 μg bid

 

207

62.6

20.8

NR

50.4

207

0

NR

Placebo

-

 

209

62.5

22.5

NR

51.1

209

1

NR

[47]

POET-COPD 2011 (Vogelmeier 2011)

Tiotropium

18 μg od

52

3707

62.9

25.6

48.0

49.2

3707

64

66

Salmeterol

50 μg bid

 

3669

62.8

25.1

48.3

49.4

3669

78

73

[66]

INSPIRE (Wedzicha 2008)

SFC

50/500 μg bid

104

658

64.0

19.0

38.0

39.1

658

21

18

Tiotropium

18 μg od

 

665

65.0

16.0

38.0

39.4

665

38

34

[24]

LHS (Wise 2000)

Triamcinolone

600 μg bid

156

559

56.2

36.0

90.5

68.5

559

15

NR

Placebo

-

 

557

56.4

37.9

89.8

67.2

557

19

NR

[39]

Zheng 2007

SFC

50/500 μg bid

24

297

66.0

9.4

21.0

47.0b

297

2

NR

Placebo

-

 

148

66.6

13.5

23.0

47.0b

148

0

NR

[48]

Zhong 2012

Budesonide + Formoterol

320/9 μg bid

26

156

65.7

1.9

NR

36.2

156

1

NR

Budesonide

400 μg bid

 

152

64.7

7.9

NR

36.3

152

0

NR

FEV1 – mean % predicted, post-bronchodilator

*Powered to detect mortality

aMean % predicted FEV1 is pre-bronchodilator

bNot stated whether mean % predicted FEV1 is pre-bronchodilator or post-bronchodilator

cFEV1 is mean of the three treatment arms

Assessment of study quality using the Cochrane risk of bias tool found that the quality of study reporting was generally high (Additional file 2: Table S2). Although all trials were randomised, 17 did not adequately describe the method of randomisation; [22, 2439] and two studies did not adequately describe methods for allocation concealment [37, 39]. With the exception of FICOPD II where the theophylline arm (not included in analysis) was open-label [36], all studies were double-blind. Reporting of loss to follow-up was unclear in 17 studies; [22, 23, 27, 29, 30, 32, 34, 37, 4047] imbalanced dropouts between the treatment groups in two studies was considered to result in a high risk of bias for the reported outcome data [39, 48]. In nine studies two or more components of the assessment were found to be potentially associated with an unclear or high risk of bias [22, 24, 27, 29, 30, 32, 34, 37, 39]. This was thought to reflect incomplete reporting rather than underlying methodological weakness in many cases.

Studies included in the analysis

Two studies were excluded from the statistical analysis. Campbell [49], was excluded since the treatment arms in this trial (formoterol + formoterol as needed, formoterol + terbutaline as needed, placebo + terbutaline as needed) were not included in any of the other trials analysed, and therefore did not link to the evidence network. Similarly, Kerstjens [41], comparing terbutaline with ipratropium bromide + terbutaline and beclomethasone + terbutaline, did not connect to the main evidence network. Two treatments were excluded from the statistical analysis. Theophylline was included in a single trial, FICOPD II (Rossi [36]), which reported no deaths, and so it was not possible for a hazard ratio to be estimated for this treatment. Similarly, the only trial including tiotropium + formoterol combination (Vogelmeier [38]) did not report any deaths for this arm, which was therefore also excluded from the analysis. The other treatment arms of these studies were included in the analysis.

The statistical analysis was based on 40 RCTs including 55,220 randomised subjects and 88,261 person years of experience, allowing the comparison of 14 treatments. Figure 2 shows the base case evidence network weighted by the number of person-years of follow up for each within-trial comparison. Reported binary mortality outcomes are presented in Table 1 and hazard ratios in Table 2. In the base case analysis hazard ratios for all-cause mortality were available for three studies and binary data were available for the remaining 37 studies.
Fig. 2
Fig. 2

Base case evidence network. The width of the lines are proportional to the total person years of follow-up for all trials informing that comparison

Table 2

All-cause mortality (hazard ratios) of included studies

Trial

Treatment

Comparator

ITT

On treatment

HR

LCI

UCI

p value

HR

LCI

UCI

p value

TORCH

SFC

Placebo

0.811

0.670

0.982

0.030

NR

NR

NR

NR

SFC

Salmeterol

0.946

0.777

1.151

0.580

NR

NR

NR

NR

SFC

Fluticasone propionate

0.768

0.636

0.927

0.006

NR

NR

NR

NR

Salmeterol

Placebo

0.857

0.710

1.035

0.110

NR

NR

NR

NR

Fluticasone propionate

Placebo

1.056

0.883

1.264

0.550

NR

NR

NR

NR

UPLIFT

Tiotropium

Placebo

0.890

0.790

1.020

0.086

0.840

0.730

0.970

0.016

POET-COPD

Tiotropium

Salmeterol

0.810

0.580

1.130

0.210

0.850

0.610

1.190

0.350

INSPIRE

SFC

Tiotropium

NR

NR

NR

NR

0.480

0.270

0.850

0.012

Base case results

Results from the fixed and random effects base case analysis are presented in Fig. 3. Hazard ratios for each treatment are compared to placebo; a hazard ratio below 1.0 indicates that the treatment is associated with reduced mortality compared to placebo. There was no evidence to suggest that the random effects model was a better fit than the fixed effects model; a difference in DIC of 2–3 is required to be indicative of improved model fit [20]. However, if we believe there is true heterogeneity between the trials, the random effects model would be more appropriate.
Fig. 3
Fig. 3

Forest plot of results of network meta-analysis. Hazard ratios compared to placebo (DIC 431.9 FE, 431.5 RE). SFC = Salmeterol fluticasone propionate combination; CrI = credible interval; Doses were pooled for the purpose of the analysis: indacaterol (150 μg od, 300 μg od), budesonide (200 μg bid, 400 μg bid, 1200 μg od for 6 months followed by 800 μg od for 30 months), fluticasone propionate (250 μg bid, 500 μg bid), salmeterol (50 μg bid, 100 μg bid), formoterol (6 μg bid, 12 μg bid, 24 μg bid) and salmeterol fluticasone propionate combination (SFC) (50/250 μg bid, 50/500 μg bid)

Two interventions produced a hazard ratio relative to placebo that did not cross 1.0 using the fixed effects model. SFC was associated with a reduction in mortality of 21 % (HR 0.79; 95 % CrI 0.67, 0.94) and indacaterol with a mortality reduction of 72 % (HR 0.28; 95 % Crl 0.08, 0.85). Using a random effects model SFC failed to show evidence of effect (HR 0.79; 95 % CrI 0.56, 1.09). For indacaterol the result using the random effects model (HR 0.29; 95 % CrI 0.08, 0.89) was comparable to that using the fixed effects model. No evidence of effect on all-cause mortality (versus placebo) was found for other treatments. Although the results for most comparators have wide credible intervals suggesting inconclusive results, the HRs for tiotropium + salmeterol, tiotropium + SFC and beclomethasone + formoterol have particularly wide credible intervals; in each case the results are generated by single, relatively small study arms therefore the uncertainty around the estimates is high.

Sensitivity analyses

Results of the sensitivity analyses did not in general differ markedly from the base case (Additional file 2: Table S3). For SFC vs placebo the relative treatment effect improved in the fixed effects analysis when unlicensed doses were excluded, but results from the random effects model showed no evidence of effect and were similar to the base case. Similarly, the relative treatment effect for indacaterol vs placebo strengthened slightly (HR 0.17, 95 % CrI 0.03, 0.78) when studies with a shorter duration were excluded.

Conclusion

In this NMA, data from 40 trials were used to inform comparisons of mortality associated with 14 different pharmacological treatments for COPD. The method allows comparisons of treatments not compared directly within individual RCTs, and provides additional information on the relative efficacy of treatments for which direct trial comparisons are available. The results show that only indacaterol and the combination of the long-acting β2-agonist salmeterol and the inhaled corticosteroid fluticasone propionate (SFC) are associated with an important reduction in the risk of all-cause mortality in COPD in fixed effect models. Although the fixed effects model was presented as the base case there was no clear difference between the fixed and random effects models (both of which are presented). The results were consistent across a number of sensitivity analyses including controlling for disease severity.

Results for SFC are based on 233 deaths occurring in 7427 subject years. The results for indacaterol are based on four deaths occurring over 1446 subject years and have wide credible intervals. These results are sensitive to the number of deaths (a small change will have a large impact on the resulting HR) and may change with further research.

The results for many of the treatments are inconclusive, as demonstrated by the wide credible intervals exhibited around a number of the HRs. Whilst tighter credible intervals are observed around the results for tiotropium, salmeterol and fluticasone, our analysis is still inconclusive as to whether the treatments provide a greater benefit or harm to patients.

Two published NMAs have evaluated the relationship between pharmacological agents and mortality in COPD patients [9, 10]. Dong [10] considered all-cause mortality and cardiovascular death as outcomes: 42 trials published up to July 2011 were included, treatments were grouped by class (long-acting β2 agonists, inhaled corticosteroids etc.) and tiotropium was separated by inhaler type. The authors sourced trial mortality results from secondary sources. The study reported a reduction in mortality for LABAs combined with ICS compared with placebo (HR 0.80; 95 % CrI 0.67, 0.94) based on a fixed effects model. Baker [9] included 28 trials reporting the mortality published up to October 2007: treatments were grouped by class. A mortality reduction reported for LABAs in combination with ICS vs placebo (HR 0.71; 95 % CrI 0.49, 0.96) in the fixed effect model.

The present analysis included an additional 14 months of reported evidence and a wider range of treatments (roflumilast, indacaterol and triamcinolone) compared with Dong [10]. Furthermore, results were not aggregated by class. An assumption of class effects presupposes that the effect of each intervention within a class is identical. Even if the assumption holds for efficacy data it may not translate to safety data as interventions could have physiological effect other than the mechanism of action, therefore we chose estimate effects for each intervention independently [50].

Binary and hazard ratio data were combined in the same analysis, permitting the maximum number of studies to be included and using the best available data from each. We minimised the risk of errors by using data only from citable sources. Sensitivity analyses were undertaken to examine the robustness of the results to the underlying assumptions.

There are a number of limitations of this study. NMA methods depend on the assumptions that effect measures are additive on the selected scale and that relative treatment effects are comparable; [8] heterogeneity between trials may invalidate this assumption. Potential observed or unobserved differences between trials may impact on heterogeneity and thereby relative treatment effects.

The majority of the studies included were not specifically designed to capture mortality as a primary or secondary endpoint. The feasibility of conducting RCTs powered to detect differences in mortality in COPD patients is limited by the need for large sample sizes with sufficient follow-up, as well as the potential for introducing bias associated with differential dropout rates across study arms. Although this is a limitation of the current analysis, where there is an absence of head-to-head trials including all comparators, NMA is a useful tool for healthcare decision makers. In the present analysis we only included studies which reported mortality in the primary study publication. Inclusion of other studies where mortality is available in secondary publications may influence the results however the relatively small number of deaths in these trials makes this unlikely [10].

A potentially beneficial impact on mortality could be masked if a large number of studies with low or ineffectual dosages are included. Whilst there is some evidence that dose responsiveness may not be a significant factor in COPD [17, 51], this could be explored further by extending the network to incorporate dose finding studies and by implementing a three-level hierarchical NMA model with an additional level for each drug class [52].

Whilst we controlled for disease severity (recorded by baseline lung function) we did not control for other potential differences between trials which may impact on relative treatment effects (e.g. background therapy, history of exacerbations) as reporting was less consistent for these indicators.

Further work could examine baseline risk or the response in the placebo arms between studies. For example, similar rates of death per 1000 patient years (PY) were observed in the indacaterol (9.9/1000 PY), budesonide (10.0/1000 PY) and triamcinolone (11.4/1000 PY) placebo arms. Much higher rates were observed in the tiotropium (37.2/1000 PY), fluticasone propionate (43.3/1000 PY), salmeterol (47.0/1000 PY) and SFC (48.7/1000 PY) placebo arms (strongly influenced by the size and number of deaths in TORCH and UPLIFT) (Additional file 2: Table S4).

We conclude that currently available data from clinical trials in COPD suggest that some pharmacological treatments may have a significant impact on mortality, compared with placebo. In particular indacaterol and the combination of salmeterol and fluticasone propionate have shown evidence of reduction in all-cause mortality. The result for indacaterol is however based on a small number of deaths occuring to subjects receiving this therapy. Further research is warranted to strengthen our conclusions.

Declarations

Acknowledgements

We would like to thank Neil Barnes, Richard Tomiak, Henrik Svedsater and Gilbert Nadeau for input on drafting the manuscript.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
ICON Health Economics and Epidemiology, Seacourt Tower, West Way, Oxford, OX2 0JJ, UK
(2)
Centre for Health Economics, University of York, York, UK
(3)
GlaxoSmithKline, Brentford, UK
(4)
Brigham and Women’s Hospital, Harvard University, Boston, MA, USA
(5)
Institute of Aging and Chronic Disease, University of Liverpool, Liverpool, UK

References

  1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448–57.PubMedView ArticleGoogle Scholar
  2. World Health Organization. The top 10 causes of death: Fact Sheet No. 310. 2014; http://www.who.int/mediacentre/factsheets/fs310/en/.
  3. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedView ArticleGoogle Scholar
  4. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest. 2009;135(5):1330–41.PubMedView ArticleGoogle Scholar
  5. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.PubMedView ArticleGoogle Scholar
  6. Institute for Quality and Efficiency in Health Care (IQWiG). General Methods 4.0. 2011 2011.Google Scholar
  7. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2014; 2014.Google Scholar
  8. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429–37.PubMedView ArticleGoogle Scholar
  9. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29(8):891–905.PubMedView ArticleGoogle Scholar
  10. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48–56.PubMedView ArticleGoogle Scholar
  11. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.PubMedPubMed CentralView ArticleGoogle Scholar
  12. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;30(20):3105–24.View ArticleGoogle Scholar
  13. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making. 1998;18(1):37–43.PubMedView ArticleGoogle Scholar
  14. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions v.5.1.0. The Cochrane Collaboration. 2011. www.cochrane-handbook.org.
  15. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10(10):54.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.PubMedPubMed CentralView ArticleGoogle Scholar
  17. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat Inhaler and the Risk of Death in COPD. N Engl J Med. 2013Google Scholar
  18. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual: Version 1.4. Cambridge: MRC Biostatistics Unit. 2003; 2003.Google Scholar
  19. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.PubMedView ArticleGoogle Scholar
  20. Spiegelhalter D, Best N, Carlin B, Van der Linde A. Bayesian Measures of model complexity and fit (with discussion). J Royal Statistical Soc. 2002;64(4):583–639.View ArticleGoogle Scholar
  21. Brooks S, Gelman A. General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat. 1998;7(4):434–55.Google Scholar
  22. Pauwels RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340(25):1948–53.PubMedView ArticleGoogle Scholar
  23. Shaker SB, Dirksen A, Ulrik CS, Hestad M, Stavngaard T, Laursen LC, et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD. 2009;6(2):104–11.PubMedView ArticleGoogle Scholar
  24. Wise R, Connett J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902–9.View ArticleGoogle Scholar
  25. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–56.PubMedView ArticleGoogle Scholar
  26. Casaburi R, Kukafka D, Cooper CB, Witek Jr TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127(3):809–17.PubMedView ArticleGoogle Scholar
  27. Chan CK, Maltais F, Sigouin C, Haddon JM, Ford GT, Group SS. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J. 2007;14(8):465–72.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–9.PubMedView ArticleGoogle Scholar
  29. Donohue JF, Van Noord JA, Bateman ED, Langley SJ, Lee A, Witek Jr TJ, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122(1):47–55.PubMedView ArticleGoogle Scholar
  30. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: Indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–62.PubMedView ArticleGoogle Scholar
  31. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102(8):1099–108.PubMedView ArticleGoogle Scholar
  32. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124(3):834–43.PubMedView ArticleGoogle Scholar
  33. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144–9.PubMedView ArticleGoogle Scholar
  34. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084–91.PubMedView ArticleGoogle Scholar
  35. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–65.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121(4):1058–69.PubMedView ArticleGoogle Scholar
  37. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.[Erratum appears in Eur Respir J. 2003 May;21(5):912]. Eur Respir J. 2003;21(1):74–81.PubMedView ArticleGoogle Scholar
  38. Vogelmeier C, Kardos P, Harari S, Gans SJM, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med. 2008;102(11):1511–20.PubMedView ArticleGoogle Scholar
  39. Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest. 2007;132(6):1756–63.PubMedView ArticleGoogle Scholar
  40. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6(5):320–9.PubMedView ArticleGoogle Scholar
  41. Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS, Sluiter HJ, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992;327(20):1413–9.PubMedView ArticleGoogle Scholar
  42. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;2:273–9.View ArticleGoogle Scholar
  43. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax. 2006;61(2):122–8.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Tonnel A-B, Perez T, Grosbois J-M, Verkindre C, Bravo M-L, Brun M. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(2):301–10.PubMedPubMed CentralGoogle Scholar
  45. Van Valk PD, Monninkhof E, Van Palen JD, Zielhuis G, Van HC. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The cope study. Am J Respir Crit Care Med. 2002;166(10):1358–63.PubMedView ArticleGoogle Scholar
  46. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–23.PubMedView ArticleGoogle Scholar
  47. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van-Mölken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103.PubMedView ArticleGoogle Scholar
  48. Zhong N, Zheng J, Wen F, Yang L, Chen P, Xiu Q, et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research & Opinion. 2012;28(2):257–65.View ArticleGoogle Scholar
  49. Campbell M, Eliraz A, Johansson G, Tornling G, Nihlen U, Bengtsson T, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med. 2005;99(12):1511–20.PubMedView ArticleGoogle Scholar
  50. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999;282(14):1371–7.PubMedView ArticleGoogle Scholar
  51. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.PubMedView ArticleGoogle Scholar
  52. Owen RK, Tincello DG, Keith RA. Network meta-analysis: development of a three-level hierarchical modeling approach incorporating dose-related constraints. Value Health. 2015;18(1):116–26.PubMedView ArticleGoogle Scholar
  53. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med. 2007;146(8):545–55.PubMedView ArticleGoogle Scholar
  54. Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460–72.PubMedView ArticleGoogle Scholar
  55. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ. 2000;320(7245):1297–303.PubMedPubMed CentralView ArticleGoogle Scholar
  56. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.[Erratum appears in Eur Respir J. 2004 Dec;24(6):1075]. Eur Respir J. 2003;22(6):912–9.PubMedView ArticleGoogle Scholar
  57. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–61.PubMedView ArticleGoogle Scholar
  58. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–94.PubMedView ArticleGoogle Scholar
  59. Calverley PM, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858–68.PubMedView ArticleGoogle Scholar
  60. Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James WY, Wedzicha JA, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Med. 2007;8:93.Google Scholar
  61. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper Jr JA, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143(5):317–26.PubMedView ArticleGoogle Scholar
  62. Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103(4):542–51.PubMedView ArticleGoogle Scholar
  63. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000.PubMedView ArticleGoogle Scholar
  64. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.PubMedView ArticleGoogle Scholar
  65. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–55.PubMedView ArticleGoogle Scholar
  66. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.PubMedView ArticleGoogle Scholar

Copyright

Advertisement